1. Krediet RT, Lindholm B, Rippe B. Pathophysiology of peritoneal membrane failure.
Perit Dial Int 20(Suppl 4):2000;S22–S42.
2. Miyata T, Devuyst O, Kurokawa K, van Ypersele de Strihou C. Toward better dialysis compatibility: advances in the biochemistry and pathophysiology of the peritoneal membranes.
Kidney Int 61:2002;375–386.
3. Williams JD, Topley N, Craig KJ, Mackenzie RK, Pischetsrieder M, Lage C, Passlick-Deetjen J; Euro Balance Trial Group. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane.
Kidney Int 66:2004;408–418.
4. Yanez-Mo M, Lara-Pezzi E, Selgas R, Ramírez-Huesca M, Domínguez-Jiménez C, Jiménez-Heffernan JA, Aguilera A, Sánchez-Tomero JA, Bajo MA, Alvarez V, Castro MA, del Peso G, Cirujeda A, Gamallo C, Sánchez-Madrid F, López-Cabrera M. Peritoneal dialysis and epithelial-to-mesenchymal transition of mesothelial cells.
N Engl J Med 348:2003;403–413.
5. Brown NJ. Aldosterone and end-organ damage.
Curr Opin Nephrol Hypertens 14:2005;235–241.
6. Rüster C, Wolf G. Renin–angiotensin–aldosterone system and progression of renal disease.
J Am Soc Nephrol 17:2006;2985–2991.
7. Remuzzi G, Perico N, Macia M, Ruggenenti P. The role of renin-angiotensin-aldosterone system in the progression of chronic kidney disease.
Kidney Int 99:2005;S57–S65.
8. Brilla CG. Renin–angiotensin–aldosterone system and myocardial fibrosis.
Cardiovasc Res 47:2000;1–3.
9. Abbas G, Silveira MG, Lindor KD. Hepatic fibrosis and the renin-angiotensin system.
Am J Ther 18:2011;e202–e208.
10. Uhal BD, Li X, Piasecki CC, Molina-Molina M. Angiotensin signalling in pulmonary fibrosis.
Int J Biochem Cell Biol 44:2012;465–468.
11. Young MJ. Mechanisms of mineralocorticoid receptor-mediated cardiac fibrosis and vascular inflammation.
Curr Opin Nephrol Hypertens 17:2008;174–180.
12. Nishimura H, Ito Y, Mizuno M, Tanaka A, Morita Y, Maruyama S, Yuzawa Y, Matsuo S. Mineralocorticoid receptor blockade ameliorates peritoneal fibrosis in new rat peritonitis model.
Am J Physiol Renal Physiol 294:2008;F1084–F1093.
13. Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD. Isolation, culture and characterization of human peritoneal mesothelial cells.
Kidney Int 37:1990;1563–1570.
14. Kang DH, Hong YS, Lim HJ, Choi JH, Han DS, Yoon KI. High glucose solution and spent dialysate stimulate the synthesis of transforming growth factor-beta1 of human peritoneal mesothelial cells: effect of cytokine costimulation.
Perit Dial Int 19:1999;221–230.
15. Williams JD, Craig KJ, Topley N, Von Ruhland C, Fallon M, Newman GR, Mackenzie RK, Williams GT; Peritoneal Biopsy Study Group. Morphologic changes in the peritoneal membrane of patients with renal disease.
J Am Soc Nephrol 13:2002;470–479.
16. Plum J, Hermann S, Fussholler A, Schoenicke G, Donner A, Röhrborn A, Grabensee B. Peritoneal sclerosis in peritoneal dialysis patients related to dialysis settings and peritoneal transport properties.
Kidney Int Suppl 78:2001;S42–S47.
17. Margetts PJ, Bonniaud P. Basic mechanisms and clinical implications of peritoneal fibrosis.
Perit Dial Int 23:2003;530–541.
18. Kim YL. The challenge of PD patients: glucose and glucose degradation products in PD solution.
Kidney Res Clin Pract 31:2012;A46–A47.
19. Jang YH, Shin HS, Sun Choi H, Ryu ES, Jin Kim M, Ki Min S, Lee JH, Kook Lee H, Kim KH, Kang DH. Effects of dexamethasone on the TGF-beta1-induced epithelial-to-mesenchymal transition in human peritoneal mesothelial cells.
Lab invest 93:2013;194–206.
20. Aguilera A, Yanez-Mo M, Selgas R, Sánchez-Madrid F, López-Cabrera M. Epithelial to mesenchymal transition as a triggering factor of peritoneal membrane fibrosis and angiogenesis in peritoneal dialysis patients.
Curr Opin Investig Drugs 6:2005;262–268.
21. Selgas R, Bajo A, Jimenez-Heffernan JA, Del Peso G, Aguilera A, López-Cabrera M. Epithelial-to-mesenchymal transition of the mesothelial cell – its role in the response of the peritoneum to dialysis.
Nephrol Dial Transplant 21(Suppl 2):2006;ii2–ii7.
22. Aroeira LS, Aguilera A, Sánchez-Tomero JA, Bajo MA, del Peso G, Jiménez-Heffernan JA, Selgas R, López-Cabrera M. Epithelial to mesenchymal transition and peritoneal membrane failure in peritoneal dialysis patients: pathologic significance and potential therapeutic interventions.
J Am Soc Nephrol 18:2007;2004–2013.
23. Noh H, Ha H, Yu MR, Kim YO, Kim JH, Lee HB. Angiotensin II mediates high glucose-induced TGF-beta1 and fibronectin upregulation in HPMC through reactive oxygen species.
Perit Dial Int 25:2005;38–47.
24. Sauter M, Cohen CD, Wornle M, Mussack T, Ladurner R, Sitter T. ACE inhibitor and AT1-receptor blocker attenuate the production of VEGF in mesothelial cells.
Perit Dial Int 27:2007;167–172.
25. Basturk T, Unsal A, Koc Y, Nezaket E, Ahbap E, Sakaci T, Sevinc M. The effects of angiotensin-converting enzyme inhibitors on peritoneal protein loss and solute transport in peritoneal dialysis patients.
Clinics (Sao Paulo) 67:2012;877–883.
26. Sun J, Yu K, Zhang H, Qun W, Rong W. Effect of renin-angiotensin system inhibitors on prevention of peritoneal fibrosis in peritoneal dialysis patients.
Nephrology 15:2010;27–32.
27. Whaley-Connell A, Habibi J, Panfili Z, Hayden MR, Bagree S, Nistala R, Hyder S, Krueger B, Demarco V, Pulakat L, Ferrario CM, Parrish A, Sowers JR. Angiotensin II activation of mTOR results in tubulointerstitial fibrosis through loss of N-cadherin.
Am J Nephrol 34:2011;115–125.
28. Brilla CG, Weber KT. Mineralocorticoid excess, dietary sodium, and myocardial fibrosis.
J Lab Clin Med 120:1992;893–901.
29. Greene EL, Kren S, Hostetter TH. Role of aldosterone in the remnant kidney model in the rat.
J Clin Invest 98:1996;1063–1068.
30. Ersoy R, Celik A, Yilmaz O, Sarioglu S, Sis B, Akan P, Yenicerioglu Y, Ormen M, Camsari T. The effects of irbesartan and spironolactone in prevention of peritoneal fibrosis in rats.
Perit Dial Int 27:2007;424–431.
31. Zhang L, Hao JB, Ren LS, Ding JL, Hao LR. The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.
Lab Invest 94:2014;839–850.
32. Vazquez-Rangel A, Soto V, Escalona M, Toledo RG, Castillo EA, Polanco Flores NA, Falcon-Chavez I, Madero M. Spironolactone to prevent peritoneal fibrosis in peritoneal dialysis patients: a randomized controlled trial.
Am J Kidney Dis 63:2014;1072–1074.
33. Bakin AV, Rinehart C, Tomlinson AK, Arteaga CL. p38 mitogen-activated protein kinase is required for TGFbeta-mediated fibroblastic transdifferentiation and cell migration.
J Cell Sci 115:2002;3193–3206.
34. Chen J, Chen JK, Harris RC. Angiotensin II induces epithelial-to-mesenchymal transition in renal epithelial cells through reactive oxygen species/Src/caveolin-mediated activation of an epidermal growth factor receptor-extracellular signal-regulated kinase signaling pathway.
Mol Cell Biol 32:2012;981–991.
35. Noh H, Kim JS, Han KH, Lee GT, Song JS, Chung SH, Jeon JS, Ha H, Lee HB. Oxidative stress during peritoneal dialysis: implications in functional and structural changes in the membrane.
Kidney Int 69:2006;2022–2028.
36. Fukuoka N, Sugiyama H, Inoue T, Kikumoto Y, Takiue K, Morinaga H, Nakao K, Maeshima Y, Asanuma M, Wang DH, Ogino K, Masuoka N, Makino H. Increased susceptibility to oxidant-mediated tissue injury and peritoneal fibrosis in acatalasemic mice.
J Nephrol 28:2008;661–668.
37. Lee H, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells.
Kidney Int 65:2004;1170–1179.
38. Ha H, Lee H. Effect of high glucose on peritoneal mesothelial cell biology.
Perit Dial Int 293(20):2000;23–26.
39. Hung KY, Liu SY, Yang TC, Liao TL, Kao SH. High-dialysate-glucose-induced oxidative stress and mitochondrial-mediated apoptosis in human peritoneal mesothelial cells.
Oxid Med Cell Longev 64:2014;2793–2805.
40. Zhang A, Jia Z, Guo X, Yang T. Aldosterone induces epithelial-mesenchymal transition via ROS of mitochondrial origin.
Am J Physiol Renal Physiol 293:2007;F723–F731.
41. Bloomfield GL, Blocher CR, Fakhry IF, Sica DA, Sugerman HJ. Elevated intra-abdominal pressure increases plasma renin activity and aldosterone levels.
J Trauma 42:1997;997–1004.
42. Selgas R, Munoz IM, Conesa J, Madero R, Gancedo PG, Carmona AR, Eugenia M, Huarte ME, Fontan MP, Sicilia LS. Endogenous sympathetic activity in CAPD patients: its relationship to peritoneal diffusion capacity.
Perit Dial Int 6:1986;205–208.
43. Zager PG, Frey HJ, Gerdes BG. Plasma 18-hydroxycorticosterone during continuous ambulatory peritoneal dialysis.
J Lab Clin Med 102:1983;604–612.
44. Zager PG, Frey HJ, Gerdes BG. Plasma concentrations of 18-hydroxycorticosterone and aldosterone in continuous ambulatory peritoneal dialysis and hemodialysis patients.
Am J Kidney Dis 3:1983;213–218.